Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CEO Dennis J. Phd Carlo sold 13,292 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $2.27, for a total transaction of $30,172.84. Following the sale, the chief executive officer now directly owns 42,353 shares in the company, valued at $96,141.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of ADMP stock traded down $0.02 during trading hours on Monday, hitting $1.98. 182,186 shares of the company were exchanged, compared to its average volume of 406,219. Adamis Pharmaceuticals Corp has a 52 week low of $1.86 and a 52 week high of $5.10. The company has a market capitalization of $94.58 million, a price-to-earnings ratio of -1.98 and a beta of 1.40.
ADMP has been the topic of several research analyst reports. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 14th. Maxim Group set a $10.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 19th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.56.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Recommended Story: Quick Ratio
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.